Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:48:48 EDT Tue 15 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:BMRN - BIOMARIN PHARMACEUTICAL - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMRN - Q0.164.79·64.830.164.82-1.59-2.4575.836,6506,34065.78  65.78  64.510670.98  49.259211:28:01Sep 1415 min RT 2¢

Recent Trades - Last 10 of 6340
Time ETExPriceChangeVolume
11:28:11Q64.8516-1.558429
11:28:11Q64.8516-1.55846
11:28:10Q64.82-1.591
11:28:09Q64.9323-1.477710
11:28:07Q64.8542-1.555875
11:28:04Q64.82-1.593
11:28:04Q64.82-1.59100
11:28:03Q64.82-1.591
11:28:02Q64.854-1.5563
11:28:02Q64.805-1.605450

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-14 09:05U:BMRNNews ReleaseBioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
2026-09-09 09:05U:BMRNNews ReleaseBioMarin Announces Positive Results of Phase 3 VOXZOGO(TM) (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
2026-09-02 09:00U:BMRNNews ReleaseBioMarin to Participate in Upcoming Investor Conferences
2026-09-01 09:05U:BMRNNews ReleaseBioMarin Announces Close of the Alesta Therapeutics Acquisition
2026-08-31 02:00U:BMRNNews ReleaseBioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
2026-08-18 08:30U:BMRNNews ReleaseBioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
2026-08-10 09:05U:BMRNNews ReleaseBioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
2026-08-06 16:03U:BMRNNews ReleaseBioMarin Reports Second Quarter 2026 Financial and Operating Results
2026-07-30 09:00U:BMRNNews ReleaseBioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
2026-07-27 09:05U:BMRNNews ReleaseBioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
2026-07-13 09:05U:BMRNNews ReleaseU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO(TM) (vosoritide) for Children With Achondroplasia
2026-06-16 09:05U:BMRNNews ReleaseBioMarin Announces New Three-Year VOXZOGO(TM) (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
2026-05-20 16:20U:BMRNNews ReleaseBioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO(TM) (vosoritide) in Children with Hypochondroplasia
2026-05-18 09:05U:BMRNNews ReleaseBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-04 16:05U:BMRNNews ReleaseBioMarin Reports First Quarter 2026 Financial and Operating Results
2026-05-02 15:30U:BMRNNews ReleaseBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO(TM) (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
2026-04-27 08:44U:BMRNNews ReleaseBioMarin Completes Acquisition of Amicus Therapeutics
2026-04-27 07:30U:BMRNNews ReleaseBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
2026-04-21 16:23U:BMRNNews ReleaseBioMarin Announces Board Leadership Transition
2026-03-12 09:05U:BMRNNews ReleaseBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO(TM) (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetic